J&J's Centocor Buy Eyes Potential $4 Bil. ReoPro Market To Spur Stent Sales
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's $4.9 bil. stock acquisition of biotechnology firm Centocor is motivated in part by the potential for Centocor's antiplatelet monoclonal antibody-based drug ReoPro (abciximab) to boost sales of coronary stents by J&J's Cordis unit.
You may also be interested in...
Centocor's ReoPro/Stent Combination Studies Could Be Attractive To J&J
Centocor's $250 mil. investment in studies to demonstrate the efficacy of its drug ReoPro in combination with coronary stents in percutaneous coronary interventions could be attractive to Johnson & Johnson, which reportedly has been in discussions to acquire the biotech firm.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.